Preskoči na sadržaj
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Jezik
Sva polja
Naslov
Autor
Tema
Signatura
ISBN/ISSN
Oznaka
Pronađi
Napredno
Traficet-EN, an oral CCR9-spec...
Citiraj ovo
Pošalji tekstualnu poruku
Pošalji ovo e-mailom
Ispiši
Izvezi zapis
Izvezi u RefWorks
Izvezi u EndNoteWeb
Izvezi u EndNote
Stalna poveznica
Traficet-EN, an oral CCR9-specific antagonist, induces high levels of remission in the open-label phase of PROTECT-1 in Crohn's disease
Pokaži ostale verzije (1)
Bibliografski detalji
Glavni autori:
Bekker, P
,
Hamilton, G
,
Johnson, D
,
Keshav, S
,
Schall, T
Format:
Conference item
Izdano:
2008
Primjerci
Opis
Ostale verzije (1)
Slični predmeti
Prikaz za djelatnike knjižnice
Slični predmeti
Traficet-EN, an Oral CCR9-Specific Antagonist, induces high levels of remission in the open-label Phase of PROTECT-1 in Crohn's Disease
od: Bekker, P, i dr.
Izdano: (2008)
Traficet-EN (CCX282-B), an orally active inhibitor of chemokine receptor CCR9, for treatment of Crohn's disease
od: Bekker, P, i dr.
Izdano: (2007)
PROTECT-1 Maintenance Phase Study Results demonstrate efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Crohn's Disease
od: Bekker, P, i dr.
Izdano: (2009)
PROTECT-1 Study Demonstrated Efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Treatment of Patients with Moderate to Severe Crohn's Disease
od: Keshav, S, i dr.
Izdano: (2009)
Protect-1, a prospective randomized oral therapy evaluation of CCX282-B (Traficet-EN) in Crohn's disease trial
od: Bekker, P, i dr.
Izdano: (2008)